Skip to main content

Table 1 Eligibility criteria, according to hospital admission status at time of enrolment

From: Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial

Criteria Inpatients (India and Australia) Virtual care patients (Australia only)
Laboratory-confirmed active SARS-CoV-2 infection within 10 days prior to randomisation, using any locally approved testing method
Aged ≥ 18 years
Be at high risk of severe disease, defined as:   
• Requiring hospital admission for the management of COVID-19 or,
• Having at least one of the following risk factors for severe disease:
- Aged ≥ 60 years
- BMI ≥ 30 kg/m2
- Diagnosis of diabetes defined as HbA1c ≥7% and/or use of glucose-lowering medication
- History of cardiovascular diseasea
- History of chronic respiratory diseasea
- Current treatment with immunosuppression
SBP ≥ 120 mmHg, or SBP ≥ 115 mmHg and receiving treatment with a non-RAAS-inhibitor blood pressure-lowering agent that can be ceased
Willing and able to perform trial procedures
Reduced eGFR in preceding 3 months, defined as < 30 mL/min/1.73m2 or the absence of an eGFR test
Reduced eGFR in preceding three months, defined as < 45 mL/min/1.73m2 or the absence of an eGFR test
Elevated serum potassium, defined as > 5.2 mmol/L, within the preceding 3 months or the absence of a serum potassium test
Receiving treatment with an ACE inhibitor, ARB, aldosterone antagonist, aliskiren or angiotensin receptor neprilysin inhibitor
Known intolerance to ARBs
Known symptomatic postural hypotension
Known biliary obstruction or severe hepatic impairment
Inability to take medications by mouth during the first 48 h after randomisation
Women who are currently pregnant or breast feeding (India)
Women < 51 years without a negative pregnancy test during the previous 3 days and/or who do not agree to use adequate contraception during the 28-day treatment period (Australia)
  1. aAs defined by the treating clinician